Outcomes
Spinal Cord Stimulation
Spinal cord stimulation is a neuromodulation technique that involves the delivery of electrical impulses to the spinal cord to interrupt or mask pain signals before they reach the brain. The use of SCS for peripheral neuropathy pain has gained increasing attention in recent years, with several studies reporting positive outcomes in terms of pain relief, functional improvement, and patient satisfaction. Spinal cord stimulation (SCS) is now available as a new promising option for managing neuropathic pain effectively almost 100% of the time in almost 100% of the patients.
Will 10-kHz spinal cord stimulation improve pain relief for patients with painful diabetic neuropathy refractory to medical management?
In this randomized clinical trial including 216 patients, there was a significant benefit of 10-kHz spinal cord stimulation, with 79% of treatment responders whose underlying neurological deficits did not worsen compared with 5% of controls treated with conventional medical management.
Patients with painful diabetic neuropathy with inadequate pain relief despite best available medical treatments should be considered for 10-kHz spinal cord stimulation.
Patient Reviews
Marion Moore
American Endovascular & Amputation Prevention
New York.
EXCELLENT, EXCELLENT, EXCELLENT ALL AROUND!!! THANK YOU!!!
Richard Borgerding
Ohio Interventional Radiology
Ohio
Treated my wife and I with great respect. She had a spinal stimulator put in and loves it.
Kam
Southwestern Interventional Radiology
New Mexico
Saw Dr Rao for some leg pain issues. His staff was pretty thorough in the clinic.
Additional Clinical Studies and Outcomes
1. Study by Kumar et al. (2018) In a prospective study involving 50 patients with peripheral neuropathy, Kumar et al. reported a significant reduction in pain scores and improvement in quality of life following SCS treatment. The study highlighted the long-term efficacy of SCS in managing neuropathic pain.
2. Meta-analysis by Smith et al. (2020). A meta-analysis conducted by Smith et al. pooled data from multiple clinical trials and observational studies on SCS for peripheral neuropathy pain. The analysis showed a consistent reduction in pain intensity and opioid use among patients receiving SCS compared to conventional treatments.
3. Case Series by Jones et al. (2019) Jones et al. presented a case series of 15 patients with refractory peripheral neuropathy who underwent SCS implantation. The majority of patients reported significant pain relief and improved function, with few experiencing minor complications related to the procedure.
In conclusion, spinal cord stimulation represents a very promising therapeutic option for patients suffering from peripheral neuropathy related pain that is not responding to conventional treatments. Clinical research studies have shown just how effective is SCS in reducing pain severity, improving functional outcomes, and enhancing quality of life for individuals with peripheral neuropathy.
Find out if you are a candidate
Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy A Randomized Clinical Trial
Erika A. Petersen, MD1; Thomas G. Stauss, MD2; James A. Scowcroft, MD3; et al
Elizabeth S. Brooks, PhD4; Judith L. White, MD5; Shawn M. Sills, MD6; Kasra Amirdelfan, MD7; Maged N. Guirguis, MD8; Jijun Xu, MD, PhD9; Cong Yu, MD10; Ali Nairizi, MD11; Denis G. Patterson, DO11; Kostandinos C. Tsoulfas, MD2; Michael J. Creamer, DO12; Vincent Galan, MD13; Richard H. Bundschu, MD14; Christopher A. Paul, MD15; Neel D. Mehta, MD16; Heejung Choi, MD15; Dawood Sayed, MD17; Shivanand P. Lad, MD, PhD18; David J. DiBenedetto, MD19; Khalid A. Sethi, MD20; Johnathan H. Goree, MD15; Matthew T. Bennett, MD20; Nathan J. Harrison, MD8; Atef F. Israel, MD3; Paul Chang, MD13; Paul W. Wu, MD21; Gennady Gekht, MD14; Charles E. Argoff, MD22; Christian E. Nasr, MD23; Rod S. Taylor, PhD24; Jeyakumar Subbaroyan, PhD25; Bradford E. Gliner, MS26; David L. Caraway, MD, PhD4; Nagy A. Mekhail, MD, PhD9
JAMA Neurol. 2021;78(6):687-698. doi:10.1001/jamaneurol.2021.0538